About: The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Creator	Ljungman, Per Styczynski, Jan Mohty, Mohamad Yakoub-Agha, Ibrahim Mikulska, Malgorzata Murray, John Grzegorz, • John, • Montoto, Silvia Arjan, • Basak, W Bregje Verhouven, • Chabannon, • Corbacioglu, Selim Dolstra, Harry Duarte, Rafael De Latour, Peffault Lankester, C Nicolaus Kröger, • Rafael De La Camara, • Régis, • Snowden, A
Source	Medline; PMC
abstract	The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT’s scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1038/s41409-020-0919-0
bibo:pmid	32410766
has license	cc-by
sha1sum (hex)	ad9fd93dace40900d2358ca81e0e0bcd7e34579c
schema:url	https://doi.org/10.1038/s41409-020-0919-0
resource representing a document's title	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
has PubMed Central identifier	PMC7220575
has PubMed identifier	32410766
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:ad9fd93dace40900d2358ca81e0e0bcd7e34579c#body_text
is schema:about of	named entity 'transplant' named entity 'developed' named entity 'coronavirus' named entity 'BOARD' named entity 'COVID-19' named entity 'WORK' named entity 'experts' named entity 'age' named entity 'European' named entity 'SARS-CoV-2' named entity 'caring' named entity 'CAR' named entity 'cellular therapy' named entity 'COVID-19' named entity 'hematopoietic cell' named entity 'SARS-CoV-2' named entity 'autologous' named entity 'coronavirus' named entity 'Risk factors' named entity 'CAR T-cell therapy' named entity 'performing' named entity 'Diagnostic procedures' named entity 'Health care workers' named entity 'Coronavirus Disease 2019' named entity 'impact of COVID-19' named entity 'animal models' named entity 'exhalation' named entity 'pediatric patients' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'comorbidities' named entity 'immunocompetent' named entity 'Remdesivir' named entity 'Remdesivir' named entity 'SARS-CoV-2' named entity 'coronaviruses' named entity 'American Society of Transplantation' named entity 'SARS-CoV' named entity 'cardiovascular disease' named entity 'PCR' named entity 'pathogens' named entity 'laminar air flow' named entity 'stem cell transplantation' named entity 'tocilizumab' named entity 'COVID' named entity 'risk factors' named entity '28 days' named entity 'Wuhan' named entity 'COVID-19' named entity 'infection' named entity 'Acute Respiratory Distress Syndrome' named entity 'COVID' named entity 'antiinflammatory' named entity 'nursing staff' named entity 'zoonotic origin' named entity 'risk assessment' named entity 'Lopinavir/ritonavir' named entity 'Supportive care' named entity 'hand hygiene' named entity 'public health'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software